Shionogi &Shionogi & Co.,Ltd.4507東証プライム医薬品FY ending Mar 2024, consolidated, IFRS
Revenue changed -3.9% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and ending equity; net assets approximate parent equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2019 | 37.3% | 0.39× | 14.6% | 1.15× | 16.9% |
| 2022 | — | —× | 9.9% | —× | — |
| 2023 | — | —× | 15.0% | —× | — |
| 2024 | 39.5% | 0.30× | 11.9% | 1.09× | 12.9% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
| Item | FY ending Mar 2019 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 |
|---|---|---|---|---|
| Revenue | 367,960 | 335,138 | 426,684 | 410,073 |
| Cost of revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pretax income | 174,043 | 126,268 | 220,332 | 198,283 |
| Income tax | — | — | — | — |
| Net income attributable to owners | 137,191 | 114,185 | 184,965 | 162,030 |
| Operating margin | — | — | — | — |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
| Item | FY ending Mar 2019 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 |
|---|---|---|---|---|
| Cash and equivalents | ¥195.8B | ¥254.4B | ¥309.2B | ¥358.1B |
| Total assets | ¥938.5B | ¥1.15T | ¥1.31T | ¥1.42T |
| Net assets | ¥813.1B | — | — | ¥1.25T |
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.